# SAREPTA THERAPEUTICS, INC. (SRPT) FY2026 Q2 P&L / Income Statement

- Company: SAREPTA THERAPEUTICS, INC. (SRPT)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001193125-26-335003
- Page: https://plicit.ai/financials/srpt/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/srpt-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-04-01 through 2026-06-30. View: Revenue categories. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 401,251,000 US dollars
- **Total cost and expenses**: 387,960,000 US dollars
- **Operating income (loss)**: 13,291,000 US dollars
- **Other income (expense), net (calculated)**: negative 15,040,000 US dollars
- **(Loss) income before income tax expense (benefit)**: negative 1,749,000 US dollars
- **Income tax expense (benefit)**: 3,141,000 US dollars
- **Net (loss) income**: negative 4,890,000 US dollars
- **Products, net**: 328,689,000 US dollars
- **Collaboration and other**: 72,562,000 US dollars
- **Cost of sales (excluding amortization of in-licensed rights)**: 149,385,000 US dollars
- **Research and development**: 91,258,000 US dollars
- **Selling, general and administrative**: 107,600,000 US dollars
- **Litigation contingency charge**: 39,000,000 US dollars
- **Amortization of in-licensed rights**: 717,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.